The blood-brain barrier is the filter between the bloodstream and the brain, formed by the tightly joined cells lining the brain’s blood vessels. Small, fat-soluble molecules tend to cross it; charged or strongly water-loving ones often do not. Whether a compound crosses is one of the first questions researchers ask about any new psychoactive candidate.
It turns up in mushroom chemistry. A 2025 rat study found that baeocystin and norpsilocin had a very limited ability to cross the barrier, and baeocystin had no significant behavioural effects (Danda et al., 2025). For bufotenine, a 2000 review argued that poor passage across the blood-brain barrier best explains its weak effects in human experiments, despite activity at psychedelic receptors (McBride, 2000).
DMT, by contrast, crosses cell membranes easily, a property a 2023 study used to show it can reach serotonin receptors inside neurons (Vargas et al., 2023). Barrier data mostly come from animals and cell models, so how much of a given compound reaches the living human brain is usually unknown.
Sources
- Danda et al., 2025, Progress in Neuro-Psychopharmacology & Biological Psychiatry
- McBride, 2000, Journal of Psychoactive Drugs: bufotenine
- Vargas et al., 2023, Science: intracellular 5-HT2A
Last checked .